Business Context and Reporting Period
This Form 8-K is a current report filed by Athira Pharma, Inc. (trading symbol: ATHA) on August 9, 2021, covering events that occurred on August 4 and August 5, 2021. The filing addresses the unexpected death of Dr. Tadataka Yamada, the Company's Chair of the Board, and subsequent leadership appointments.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document is limited to reporting corporate governance events.
Material Changes
- Board Leadership Change: Dr. Tadataka Yamada, who served as a director since June 2019 and Chair of the Board since January 2020, died unexpectedly of natural causes on August 4, 2021.
- New Appointments: On August 5, 2021, the Board appointed Kelly A. Romano as the new Chair of the Board. Additionally, Barbara Kosacz was appointed Chair of both the Compensation Committee and the Nominating and Corporate Governance Committee.
- Committee Composition: The Compensation Committee now consists of Barbara Kosacz (Chair) and Joseph Edelman. The Nominating and Corporate Governance Committee now consists of Barbara Kosacz (Chair), Joseph Edelman, and John Fluke.
Outlook, Risks, and Management Commentary
The filing includes a press release mourning Dr. Yamada's passing, highlighting his extensive background in medicine, science, and corporate leadership, including roles at Takeda Pharmaceuticals, GlaxoSmithKline, and the Bill and Melinda Gates Foundation. The Company has taken immediate steps to ensure continuity of governance by appointing Ms. Romano, who brings over 30 years of executive operating experience in technology and aerospace, and Ms. Kosacz to lead key committees. No specific financial risks, guidance, or unusual items are disclosed in this report.
Key Facts for Investor Verification
- Verify the effective date of the new Board Chair and committee leadership appointments (August 5, 2021).
- Review the full press release (Exhibit 99.1) for additional details on the Company's tribute to Dr. Yamada.
- Confirm the updated composition of the Board of Directors and its committees in subsequent filings.
- Note that this filing contains no financial performance data; refer to the most recent 10-Q or 10-K for financial metrics.